BioCryst Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- BioCryst Pharmaceuticals's estimated annual revenue is currently $114M per year.
- BioCryst Pharmaceuticals received $100.0M in venture funding in February 2019.
- BioCryst Pharmaceuticals's estimated revenue per employee is $197,969
- BioCryst Pharmaceuticals's total funding is $1.3B.
- BioCryst Pharmaceuticals's current valuation is $2.8B. (January 2022)
Employee Data
- BioCryst Pharmaceuticals has 576 Employees.
- BioCryst Pharmaceuticals grew their employee count by 10% last year.
BioCryst Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
2 | Chief Business Development Officer | Reveal Email/Phone |
3 | Chief Strategy Officer | Reveal Email/Phone |
4 | Sr. VP Regulatory Affairs | Reveal Email/Phone |
5 | Chief Business Development Officer | Reveal Email/Phone |
6 | Sr. VP Global Supply Chain | Reveal Email/Phone |
7 | VP | Reveal Email/Phone |
8 | VP | Reveal Email/Phone |
9 | Sr VP Development | Reveal Email/Phone |
10 | VP, General Manager Iberia | Reveal Email/Phone |
BioCryst Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11.2M | 72 | -13% | N/A | N/A |
#2 | $5099.8M | 32902 | -4% | N/A | N/A |
#3 | $1.7M | 11 | 0% | N/A | N/A |
#4 | $0.6M | 4 | -56% | N/A | N/A |
#5 | $0.9M | 11 | -39% | N/A | N/A |
#6 | $1.7M | 11 | 10% | N/A | N/A |
#7 | $0.6M | 4 | -33% | N/A | N/A |
#8 | $4.8M | 31 | -6% | N/A | N/A |
#9 | $6.4M | 41 | 3% | N/A | N/A |
#10 | $4.2M | 27 | -18% | N/A | N/A |
What Is BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. Founded in 1986, BioCryst has more than 50 employees and is experiencing continued growth. The Company's headquarters are located in Research Triangle Park, North Carolina and its Discovery Center of Excellence is in Birmingham, Alabama. With expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. We are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. The commitment of BioCryst remains unchanged. We continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$1.3B
Total Funding
576
Number of Employees
$114M
Revenue (est)
10%
Employee Growth %
$2.8B
Valuation
N/A
Accelerator
BioCryst Pharmaceuticals News
EverSource Wealth Advisors LLC purchased a new position in shares of BioCryst Pharmaceuticals in the 4th quarter worth $41,000. Janus Henderson...
American biotech BioCryst Pharmaceuticals (BCRX 4.74%) scored an important regulatory win across the Atlantic Ocean on Wednesday.
Shares of BioCryst Pharmaceuticals (BCRX -2.81%) took it on the chin Monday, suffering a nearly 7% decline in value. Not for the first time...
BioCryst is filling its coffers again — this time in $350 million cash with the help of both old and new investors. The Durham, NC biotech reported this morning that it inked yet another deal alongside a familiar name — Royalty Pharma for $200 million. Royalty was the same com ...
—Provides funding for BCX9930/oral Factor D program across multiple indications— —Agreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity— NEW YORK, RESEARCH TRIANGLE PARK, N.C. and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuti ...
Other Companies in Durham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $107.9M | 586 | 5% | $26.3M |
#2 | $35M | 591 | -1% | $161M |
#3 | $266.5M | 604 | 3% | N/A |
#4 | $140.2M | 623 | N/A | N/A |
#5 | $218.7M | 648 | 3% | N/A |
BioCryst Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2004-02-18 | $21.4M | Common Stock | Article | |
| 2007-08-07 | $65.3M | Undisclosed | Article | |
| 2009-11-20 | $56.1M | Undisclosed | Morgan Stanley | Article |
| 2011-03-10 | $30.0M | Undisclosed | Morgan Stanley & Co Incorporat | Article |
| 2013-08-01 | $17.6M | Undisclosed | Wells Fargo Securities, JMP Securities | Article |
| 2014-05-29 | $115.0M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2016-09-27 | $23.0M | Undisclosed | Midcap Financial | Article |
| 2017-03-13 | $51.7M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2017-09-13 | $92.0M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2019-02-08 | $100.0M | Undisclosed | Midcap Financial Trust | Article |